Clinical outcomes of long-term inhaled combination therapies in patients with bronchiectasis and airflow obstruction

Table 4 Effect of clinical factors contributing to the annual FEV₁ change (mL/yr)

	Adjusted β-coefficient (95% CI)	P-value
Age	-4.18 (-6.19–-2.17)	< 0.001
Female	-121.15 (-172.84–-69.47)	< 0.001
BMI	11.29 (5.99–16.59)	< 0.001
Current smoker	-76.61 (-123.54–-29.69)	0.001
mMRC grade	-34.12 (-62.31–-5.93)	0.018
Baseline FEV₁(100 mL)	75.25 (70.17–80.32)	< 0.001
Previous moderate or severe exacerbation history	-50.51 (-97.51–-3.50)	0.036
Inhaled therapy (ref: LABA/LAMA)
ICS/LABA	-49.73 (-105.47–6.01)	0.081
ICS/LABA/LAMA	48.83 (-1.94–99.59)	0.060

Note: Data were analyzed with mixed linear regression and are presented as linear regression coefficient and standard error. BSI and FACED were omitted from the multivariable analysis due to concerns of collinearity with other clinical variables.
Abbreviations: BMI, body mass index; FEV₁, forced expiratory volume in 1 second; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist

ISSN: 1471-2466